Rhythm Pharmaceuticals Rare Obesity Drug Study Disappoints

All NewsMarch 17, 2026

Rhythm Pharmaceuticals says EMANATE trial misses goals, despite BMI reduction signals and continued pipeline development plans.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent